NICE Endorses Natalizumab RRMS Treatment Expans...

By João L. Carapinha

January 9, 2026

NICE Expands Access to Natalizumab RRMS Treatment for Highly Active Cases The National Institute for Health and Care Excellence (NICE) has issued final draft ...
Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Thro...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity
Positive ARTISTRY-2 Trial Results for BIC LEN HIV Regimen
Accelerating Tec-Dara Multiple Myeloma Therapy Review: A Game Changer for Pat...
CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggress...
Arexvy RSV Vaccine Expansion: Broader Access and Impact on Adult Health Outcomes
Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Co...
2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solut...
NICE Approves Seven Digital Cardiac Rehabilitation Technologies for Enhanced ...